Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-07-08
2008-07-08
Solola, Taofiq A (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S400000
Reexamination Certificate
active
07396856
ABSTRACT:
Novel benzopyran analogs are disclosed. Also disclosed are methods for the lowering and controlling of normal or elevated intraocular pressure as well as a method for the treatment of glaucoma using compositions containing one or more of the compounds of the present invention.
REFERENCES:
patent: 4690931 (1987-09-01), Wick et al.
patent: 5011846 (1991-04-01), Gittos et al.
patent: 5151444 (1992-09-01), Ueno et al.
patent: 5290781 (1994-03-01), Espino et al.
patent: 5296504 (1994-03-01), Stjernschantz et al.
patent: 5352708 (1994-10-01), Woodward et al.
patent: 5422368 (1995-06-01), Stjernschantz et al.
patent: 5494928 (1996-02-01), Bös
patent: 5538974 (1996-07-01), Ogawa et al.
patent: 5561150 (1996-10-01), Wichmann
patent: 5571833 (1996-11-01), Kruse et al.
patent: 5578612 (1996-11-01), Macor et al.
patent: 5646173 (1997-07-01), Bös et al.
patent: 5652272 (1997-07-01), Ogawa et al.
patent: 5693654 (1997-12-01), Birch
patent: 5874477 (1999-02-01), McConnell et al.
patent: 5889052 (1999-03-01), Klimko et al.
patent: 5902815 (1999-05-01), Olney et al.
patent: 6107324 (2000-08-01), Behan et al.
patent: 6660870 (2003-12-01), Ruskinko et al.
patent: 6664286 (2003-12-01), May et al.
patent: 6696476 (2004-02-01), Chen et al.
patent: 6806285 (2004-10-01), May et al.
patent: 6884816 (2005-04-01), May et al.
patent: 2003/0181503 (2003-09-01), May et al.
patent: 0 771 563 (2003-01-01), None
patent: WO 92/00338 (1992-01-01), None
patent: WO 94/03162 (1994-02-01), None
patent: WO 94/13275 (1994-06-01), None
patent: WO 97/35579 (1997-10-01), None
patent: WO 98/18458 (1998-05-01), None
patent: WO 98/31354 (1998-07-01), None
patent: WO 98/56768 (1998-12-01), None
patent: WO 99/59499 (1999-11-01), None
patent: WO 00/12475 (2000-03-01), None
patent: WO 00/12510 (2000-03-01), None
patent: WO 00/16761 (2000-03-01), None
patent: WO 00/35922 (2000-06-01), None
patent: WO 00/44753 (2000-08-01), None
patent: WO 00/77002 (2000-12-01), None
patent: WO 00/77010 (2000-12-01), None
patent: WO 01/40183 (2001-06-01), None
patent: WO 01/70207 (2001-09-01), None
patent: WO 01/70222 (2001-09-01), None
patent: WO 01/70223 (2001-09-01), None
patent: WO 01/70230 (2001-09-01), None
patent: WO 01/70701 (2001-09-01), None
patent: WO 01/70702 (2001-09-01), None
patent: WO 01/70745 (2001-09-01), None
patent: WO 01/85152 (2001-11-01), None
patent: WO 02/098350 (2002-12-01), None
patent: WO 02/098400 (2002-12-01), None
patent: WO 02/098860 (2002-12-01), None
patent: WO 03/051291 (2003-06-01), None
patent: WO 03/051352 (2003-06-01), None
patent: WO 03/053436 (2003-07-01), None
patent: WO 04/019874 (2004-03-01), None
patent: WO 04/028451 (2004-04-01), None
patent: WO 04/054572 (2004-07-01), None
patent: WO 04/058725 (2004-07-01), None
King, Med. Chem: Principle and Practice (1994), p. 206-208.
Bowen et al., “Nonlinear regression using spreadsheets,”Trends In Pharmacological Sciences, vol. 16, pp. 413-423 (1995).
Chang et al., “Mechanism of the Ocular Hypotensive Action of Ketanserin,”J. of Ocular Pharmacology, vol. 1(2), pp. 137-147 (1985).
Gupta et al., “Therapeutic Potentials of 5-HT Receptor Modulators,”Indian J. of Pharmacology, vol. 26, pp. 94-107 (1994).
Krootila et al., “Effect of Serotonin and Its Antagonist (Ketanserin) on Intraocular Pressure in the Rabbit,”J. of Ocular Pharmacology, vol. 3(4), pp. 279-290 (1987).
Mallorga et al., “Characterization of Serotonin Receptors in the Iris + ciliary body of the albino rabbit,”Current Eye Research, vol. 6(3), pp. 527-532 (1987).
Mano et al., “The Effect of Anplag (Sarpogelate HCL), New Selective 5-HT2Antagonist on Intraocular Pressure in Rabbits,”IOVS, vol. 36(4), S719 (1995).
May et al., “A Novel and Selective 5-HT2Receptor Agonist with Ocular Hypotensive Activity: (S)-(+)-1-(2-Aminopropyl)-8,9-dihydropyrano[3,2-e]indole,”J. Med. Chem., vol. 46, pp. 4188-4195 (2003).
May et al., “Evaluation of the Ocular Hypotensive Response of Serotonin 5-HT1Aand 5-HT2Receptor Ligands in Conscious Ocular Hypertensive Cynomolgus Monkeys,”J. of Pharmacology and Experimental Therapeutics, vol. 306(1), pp. 301-309 (2003).
Osborne et al., “Do Beta-Adrenoceptors and Serotonin 5-HT1A Receptors have Similar Functions in the control of Intraocular Pressure in the Rabbit?”,Ophthalmologica, vol. 210, pp. 308-314 (1996).
Osborne et al., “5-Hydroxytryptamine1Aagonists: potential use in glaucoma. Evidence from animal studies,”Eye, vol. 14(38), pp. 454-463 (2000).
Takeda et al., “The Effect of Inplag. Novel Selective 5-HT2Antagonist on Intraocular Pressure in Glaucoma Patients,” IOVS, Vo. 36(4), S734 (1995).
Wang et al., “Effect of 5-methylurapldil, an α1a- adrenergic antagonist and 5-hydroxytryptamine1aagonist, on aqueous humor dynamics in monkeys and rabbits,”Current Eye Research, vol. 16(8), pp. 769-775 (1997).
Wang et al., “Effect ofpMPPI Hydrochloride (p-MPPI) Applied before 5-methylurapidill (5-MU) on Intraocular Pressure (IOP) In Normal Monkeys,”IOVS, vol. 39(4) (1998).
Hellberg Mark R.
Namil Abdelmoula
Alcon Inc.
Kilyk & Bowersox P.L.L.C.
Solola Taofiq A
LandOfFree
Benzopyran analogs and their use for the treatment of glaucoma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzopyran analogs and their use for the treatment of glaucoma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzopyran analogs and their use for the treatment of glaucoma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2804215